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Cardiovascular Actions of Neurotrophins
ANDREA CAPORALI and COSTANZA EMANUELI
Division of Experimental Cardiovascular Medicine, Bristol Heart Institute, University of Bristol,
Bristol, United Kingdom
Abstract
Neurotrophins were christened in consideration of their actions on the nervous system and, for a
long time, they were the exclusive interest of neuroscientists. However, more recently, this family
of proteins has been shown to possess essential cardiovascular functions. During cardiovascular
development, neurotrophins and their receptors are essential factors in the formation of the heart
and critical regulator of vascular development. Postnatally, neurotrophins control the survival of
endothelial cells, vascular smooth muscle cells, and cardiomyocytes and regulate angiogenesis and
vasculogenesis, by autocrine and paracrine mechanisms. Recent studies suggest the capacity of
neurotrophins, via their tropomyosin-kinase receptors, to promote therapeutic neovascularization
in animal models of hindlimb ischemia. Conversely, the neurotrophin low-affinity p75NTR
receptor induces apoptosis of endothelial cells and vascular smooth muscle cells and impairs
angiogenesis. Finally, nerve growth factor looks particularly promising in treating microvascular
complications of diabetes or reducing cardiomyocyte apoptosis in the infarcted heart. These
seminal discoveries have fuelled basic and translational research and thus opened a new field of
investigation in cardiovascular medicine and therapeutics. Here, we review recent progress on the
molecular signaling and roles played by neurotrophins in cardiovascular development, function,
and pathology, and we discuss therapeutic potential of strategies based on neurotrophin
manipulation.
I. INTRODUCTION
Neurotrophins (NTs) are a family of proteins that have been implicated in several functions
of the nervous system, including axonal growth, synaptic plasticity, survival, differentiation,
and myelination (43, 115, 161). Nerve growth factor (NGF), probably the most extensively
studied member of NTs, was discovered by Rita Levi-Montalcini and characterized for its
ability to stimulate growth, differentiation, and survival of neurons during development and
after injury (52, 151). In the early 1980s, Hofer and Barde (111) identified and purified a
brain protein that they named brain-derived neurotrophic factor (BDNF). Like NGF, BDNF
promotes survival and neurite outgrowth of sensory neurons. Based on the homologies
between the primary structures of NGF and BDNF, two years later Jones and Reichardt
(124) reported the cloning of a third member of the NTs family, neurotrophin-3 (NT-3). In
addition to NGF, BDNF, and NT-3, three other NTs have been identified: neurotrophin-4/5
(NT-4/5) (also known as NT-4) (120) and, limited to fishes, NT-6 and NT-7, which probably
do not have mammalian orthologs (94, 189). The components of the NTs family and their
signaling receptors are described in sections II and III. Since NTs were discovered by
neuroscientists, initial attention focused on their actions on the developing and mature
nervous system. However, strong evidence has emerged that NTs exert important
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cardiovascular functions, which largely exceed their implication in the neural regulation of
the heart function (106, 117, 118). Developmental studies (reviewed in sect. IV), which
were performed in the late 1990s on global knockout murine models, pointed to the role of
NT-3 and BDNF in the formation of the heart and the myocardial vasculature (69, 70, 257,
258). These results represented the kick-off for investigating direct actions of NTs on the
adult cardiovascular system and its cellular components. At present, we know that NTs
promote angiogenesis and control the survival of adult endothelial cells (EC), vascular
smooth muscle cells (VSMC), and cardiomyocytes (sect. V), yet these investigations need to
be significantly expanded. Therefore, we auspicate that this review will propel new interest
in researching the functions of NTs in cardiovascular physiology and pathology and in
characterizing the underpinned signaling pathways. The importance of the discovery that
NTs act on cardiovascular cells by autocrine mechanisms has recently been cross-fertilized
by the understanding that the prototypic angiogenic factor vascular endothelial growth factor
A (VEGF-A) is produced by neurons (195). VEGF-A exerts neuroprotection not only by
maintaining the trophism of vasa nervosum (235), but also by directly targeting VEGF
receptors expressed by neurons (197). Therefore, although named in agreement with their
first identified action, several growth factors look to be acting at multiple cell targets as well
as being produced by cells belonging to different systems. In line with this viewpoint, far
away from negating a fundamental neural role of NTs, we want to outline the importance of
this class of molecules for determining and maintaining the cardiovascular phenotype. Once
the role of NTs in cardiovascular physiology is established, this review will progress to
address the possible involvement of NTs in pathological angiogenesis and atherosclerosis
(sect. VI) and to propose potential clinical targets of NTs (sect. VII). Preclinical studies
suggest the capacity of NTs to promote therapeutic neovascularization of ischemic limb
muscles (78, 95, 131, 229) and diabetic skin ulcers (95). NTs look particularly promising in
treating microvascular complications of diabetes, as they have been shown to reduce
diabetes-induced apoptosis of EC and promote vascular regeneration (95, 229). Moreover, in
diabetes, cardiovascular complications are usually accompanied by neuropathy, which can
also be treated by NTs. It is possible therefore to envisage the use of NTs to cure diabetic
cutaneous ulcers and diabetes-associated erectile dysfunction. In view of the antiapoptotic
action of NGF on cardiac myocytes, NTs may be a therapeutic target for diabetic
cardiomyopathy, which is characterized by exaggerated cardiovascular apoptosis,
microvascular rarefaction, and neuropathy. Despite their amazing therapeutic potential, NTs
are not considered ideal drug candidates. In fact, they show a poor pharmacokinetic behavior
and bind, although with different affinity, two receptor types (trk and p75NTR), which can
command opposite actions. Moreover, pain has been described as a side effect of
recombinant NGF-based experimental therapy of diabetic neuropathy (8). However, several
approaches (described in sect. VII) may allow overcoming these drawbacks.
II. NEUROTROPHINS AND NEUROTROPHIN RECEPTORS
A. Neurotrophins and Pro-Neurotrophins
NGF is a glycoprotein of 118 amino acids, consisting of three subunits (α, β, and γ
complex). The α-NGF subunit appears inactive (247). The β-NGF is responsible for the
NGF biological activity, while the γ-NGF is a highly specific active protease (26-kDa serine
protease of the kallikrein protease group) that is able to process NGF precursor to its mature
form. NGF is part of the NT family of molecules, which includes BDNF, NT-3, and NT-4/5.
Fishes also possess NT-6 and NT-7. With the exception of NT-4/5, NTs are highly
conserved from fishes to mammals (99), thus sharing a similar molecular mass (13.2–15.9
kDa), isoelectric points (range of 9 –10), and 50% identity in primary structure (178). NTs
generally function as noncovalently associated homodimers, but at least some NT subunits
are able to form heterodimers with other NT subunits. The crystal structures of β-NGF,
NT-3, and NT-4/5 homodimers and the BDNF monomer have been determined (30, 172,
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222). The structural hallmark of these four proteins is a characteristic arrangement of the
disulfide bridges, known as the cystine knot, also identified in other secreted proteins (173).
NTs are produced as 30- to 35-kDa proproteins consisting of a preprodomain, a prodomain,
and a mature domain that are proteolytically cleaved to produce mature proteins (12–13
kDa). Until recently, little consideration was paid to the NTs prodomain, which was thought
to be only involved in protein folding and in regulation of NTs secretion (253). However,
following the understanding that pro-NTs are highly secreted in different tissues (29, 81)
and that prodomain regions have highly conserved sequences across species, Lee et al. (149)
demonstrated that pro-NTs possess biological actions, which are different from those
elicited by mature NTs. Furthermore, the presence of a prodomain induces restrictions on
the conformation of pro-NTs, thus preventing their interaction with trk receptors (199).
Intracellular posttranslational modifications to remove the predomains and glycosylates/
glycosulfates specific residues present in the prodomain have been performed (237). These
modifications are thought to be responsible for the efficient trafficking of pro-NTs from the
endoplasmic reticulum. Subsequently, this trafficking allows the majority of pro-NTs to
undergo intracellular cleavage by furin-like proprotein convertases at the consensus site R-
X-K/R-R (arginine-unspecified amino acid-lysine/arginine-arginine). The mature proteins
form noncovalent symmetrical homodimers and are then secreted into the extracellular
environment (44, 178). Lee et al. (149) were the first to demonstrate that also pro-NTs can
be secreted from the cell and processed in the extracellular compartment to mature NTs. For
example, pro-BDNF can be secreted from neurons (29, 178) and also by a line of EC (149).
Mature BDNF can derive from the cleavage of pro-BDNF by extracellular proteases,
including the matrix metalloproteinases-3 (MMP-3) and -7 (MMP-7) (149). Another
protease that cleaves pro-NTs is the serine protease plasmin (178). This enzyme derives
from the proteolytic cleavage of plasminogen by the tissue plasminogen activator (tPA)
(207). A recent study demonstrated that NTs upregulate plasminogen gene expression
through two Sp1 (Specificity protein 1) binding site on plasminogen promoter, thus creating
a positive feedback for the maturation of NTs (97).
B. Neurotrophin Receptors
The search for a receptor for NTs led to the discovery of two distinct ones: the tropomyosin
kinase receptors (trks) and the neurotrophin receptor p75 (p75NTR) (123, 127, 138). It is now
well established that survival signaling is predominantly associated with trk activation. In
contrast, p75NTR, with some exceptions, has a critical role in apoptosis of neuronal and
nonneuronal cells.
1. Tropomyosin kinase receptors—The trk receptors A, B, and C are typical tyrosine
kinase receptors. TrkA was first cloned by two separate research groups (127, 138),
followed later on by trkB and trkC (13, 127). Initially, different NTs were believed to bind
preferentially to specific trk receptors: NGF to trkA, BDNF and NT-4/5 to trkB, and NT-3 to
trkC. However, NT-3 can also bind to trkA and trkB (51, 252). Ligand specificity can be
influenced by inserting variants in the extracellular domain of trkA and trkB. Splice variants
have been described for all the three trk receptors, including deletions in the extracellular
domain or intracellular truncations of the tyrosine kinase domain (242). Interestingly, the
truncated trk splice variants act as dominant negative modulators of trk signaling (75, 191).
In trks, the tyrosine kinase domains are highly conserved (~80% amino acid identity) and
the extracellular domains are more different (~30% amino acid identity). The extracellular
domain of trk receptors is composed of three leucine-rich motifs flanked by two cysteine
clusters, two immunoglobulin-like C2 type domains (Ig-C2), a single transmembrane
domain, and a cytoplasmic region with a kinase domain. Binding of NTs to trk receptors
occurs mainly through the Ig-C2 domains, helped by the transmembrane domain (206, 263).
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Like for the other tyrosine kinase receptors, phosphorylation of the cytoplasmatic tyrosines
regulates their activity and provides the recruitment of adaptor molecules that mediate
initiation of signaling cascades (234).
Trk receptors are present on vascular EC (34, 135, 255), VSMC (132, 184), and
cardiomyocytes (36, 128, 154). The finding that vascular cells and myocytes produce and
secrete NGF (34) suggests an autocrine control of cardiovascular cell functions by NTs.
Unpublished data from our laboratory show that endothelial progenitor cells (EPC) from
bone marrow and peripheral blood express trkB and trkA that are responsive to stimulation
by BDNF and NGF. In contrast, EPC do not express trkC and are not responsive to
stimulation with NT-3 (unpublished observations).
2. p75NTR—The p75NTR, which was the first receptor to be identified for NGF, belongs to
the tumor necrosis factor (TNF) receptor superfamily, thus sharing the overall structure of
TNF-α p55 receptor, but not the ability to bind TNF-α (123). Similar to the other TNF
superfamily members, p75NTR contains four cysteine-rich motifs, a transmembrane domain,
and a cytoplasmic death domain. However, unlike other TNF superfamily receptors, p75NTR
does not exhibit trimerization. For eliciting its proapoptotic effect, p75NTR must be in its
monomeric form, as dimerization or homomultimerization completely suppresses p75NTR-
induced apoptosis (212, 271). In addition, the p75NTR death domain conformation,
consisting of two perpendicular sets of three helices packed into a globular structure, differs
from that of the other TNF receptor family members (152). No catalytic activity has been
identified for p75NTR intracellular domain (45), and the majority of the p75NTR signals
described to date are mediated by associations with cytoplasmic interactors (see below).
Moreover, unlike other death receptors, including Fas/Apo-1/CD95 and the TNF-α p55
receptor, p75NTR does not require the apoptotic adaptor molecules Fas-associated death
domain (FADD) and TNF receptor-associated death domain protein (TRADD) to induce
apoptosis in neural cells (273). In contrast, the interaction between p75NTR and TRADD is
required for activation of NFκB, which controls the antiapoptotic effect of NGF in breast
cancer cells (77).
In contrast to the specificity of the trk receptors, each of the mature NTs binds p75NTR with
equivalent affinity, but with unique kinetics (224, 225). The crystal structure of NGF in
complex with the extracellular domain of p75NTR has been crystallized, revealing a
stoichiometry of 2 NGF:1 p75NTR, a sort of trimeric ligand-receptor complex. The
interaction between p75NTR and NGF reportedly results in conformational changes in NGF,
which prevent the formation of p75NTR dimers (105). Wehrman et al. (275) recently showed
that p75NTR and trkA could bind to NGF in a 1:2:1 stoichiometry (1 trkA:2 NGF:1 p75NTR).
This ternary complex, in which the receptors are arranged in opposite orientations, requires
that the extracellular domains of both receptors are arranged to overlap NGF protein (275).
In neural cells, p75NTR and trk receptors are often coexpressed to form a complex that can
be immunoprecipitated (20). p75NTR/trkA receptor association leads to the formation of a
high-affinity NT binding site (108), which is abolished by mutations in the cytoplasmic or
transmembrane domains of any of the two receptors (80). The affinity between NTs and trk
receptors is modulated by p75NTR, which in fact increases ligand discrimination by the trk
receptors (15, 20, 176).
It has been shown that, in the presence of the coreceptor sortilin (a Vps10-domain receptor),
a furin-resistant mutant of pro-NGF binds to p75NTR with five times greater affinity than
mature NGF, while the same mutant has no affinity for trkA (149, 193). Similarly, in the
presence of sortilin, pro-BDNF binds with high affinity to p75NTR, and it does not activate
trkB (256). Both pro-NGF and pro-BDNF, via p75NTR, induce cell apoptosis (149, 256).
Secretion of pro-NT-3 or pro-NT-4/5 has not been reported to date. Pro-NGF and pro-BDNF
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reportedly bind with high affinity to a complex of p75NTR with sortilin. Both sortilin and
p75NTR directly participate in binding the prodomain of pro-NGF or pro-BDNF. It has been
pre-posed that the presence or absence of sortilin determines whether or not p75NTR acts as
a death receptor (193). Recent data demonstrate that sortilin deficiency does not affect
developmentally regulated apoptosis of sympathetic neurons, but it prevents their age-
dependent degeneration, thus suggesting that sortilin possesses also distinct roles from
apoptotic signaling (122). Finally, p75NTR has been proposed to be a dependence receptor,
i.e., a receptor which responds to ligand withdrawal by caspase activation and apoptosis, as
reviewed by Bresden et al. (27).
p75NTR is scarcely expressed by EC or VSMC cultured under basal culture conditions and
in healthy mice (34, 35, 229, 272). Its expression by vascular cells is induced in pathological
conditions, such as ischemia, atherosclerosis, and diabetes (34, 35, 229, 272). p75NTR is also
present in pericytes and perivascular mesenchymal cells in tumors (82). The expression of
p75NTR by healthy or diseased cardiomyocytes has not been investigated, yet. Reports show
that pro-BDNF is secreted by cells of a mouse EC line (146) and that exogenous pro-NGF
engages p75NTR expressed by a transformed rat brain EC line (RBE4), thus triggering
apoptosis. We recently showed that p75NTR transduction induces apoptosis of human
umbilical vein EC (HUVEC), microvascular EC (HMVEC), and EPC (35). To date, no
evidence exists on whether pro-NT is released from primary cultures of cardiovascular cells
or exerts any action on cardiovascular cells.
In summary, mature NTs bind to trk alone or complexed with p75NTR for prosurvival
signaling, while pro-NGF and pro-BDNF bind exclusively to p75NTR and trigger apoptotic
events. P75NTR can induce apoptosis in the absence of a ligand. In conclusion, the ratio of
trk and p75NTR receptors, the proteolytic processing of pro-NTs, and the ability of cross-
linking with coreceptor are critical events governing life and death in neural and nonneural
cells.
III. SIGNALING OF NEUROTROPHIN RECEPTORS
A. Trk Receptor Signaling
Trks act as typical tyrosine kinase receptors, which, following interaction with mature NT
ligands, are activated by dimerization and phosphorylation in trans (115). Trk receptors are
not activated by pro-NTs (149). Thus the proteases that control maturation of pro-NTs (see
below) also regulate activation of trk receptors.
The cytoplasmic domains of the trk receptors contain five tyrosines (Y490, Y785, Y670,
Y674, and Y675) which are essential for receptor signaling. When phosphorylated, the
tyrosines constitute the binding sites for adaptor proteins that are intermediates in
intracellular signaling cascades (115). In particular, Y490 and Y785 primarily recruit Shc
and phospholipase C-γ (PLC-γ), respectively, while Y670, Y674, and Y675 can also
engage adaptor proteins, including SH2B, adaptor protein containing PH and SH domains
(APS), fibroblast growth factor receptor substrate 2 (Frs2), and growth factor receptor-
bound protein 2 (Grb2) (163, 210, 251).
The major pathways activated by the trk receptors are Ras/Rap-mitogen-activated protein
kinase (MAPK)/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase
(PI3K)-Akt, and PLC-γ (115). Finally, activation of the small GTPase Ras in response to
NTs has been shown and linked to survival and differentiation (98).
1. Ras/Rap-MAPK/ERK—NGF-induced phosphorylation of trkA at Y490 provides a
recruitment site for binding of the adaptor protein Shc. Next, Shc recruits Grb2 complexed
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with SOS which then activates Ras (190). Activation of Ras promotes signaling through
several downstream pathways, including PI3K, Raf, and p38 MAPK (266). Raf
phosphorylation triggers the sequential activation of MEK1 (meiotic kinase) and/or MEK2
and then the phosphorylation of Erk1 and Erk2 by MEK1 or MEK2 (79). By a negative-
feedback loop, MEK activation can stop the signaling of Ras by phosphorylating SOS to
disrupt the Grb2-SOS complex (126).
The stimulation of Ras induced by trk receptors promotes only transient MAPK activation
(167). In contrast, prolonged Erk activation depends on a distinct signaling pathway and
requires the adaptor protein Crk, the guanine nucleotide exchange factor C3G, the small
GTPase Rap1, the protein tyrosine phosphatase Shp2, and the serine threonine kinase B-Raf
(96, 126). NGF-induced trkA activation leads to Frs2 recruitment at phosphorylated Y490.
Frs2 phosphorylation by activated trkA provides binding sites for Grb2 and Crk (175).
Association with Crk results in activation of C3G. C3G then activates Rap1, which
eventually signals further downstream through B-Raf, thus resulting in a prolonged MAPK
signaling (192). Recent studies identified a new ankyrin repeat-rich membrane-spanning
protein (ARMS), which represents a link between trkA and Crk (119). Interaction between
ARMS and Crk, which increases upon NGF treatment, modulates the activation of Rap1 and
subsequently of MAPK pathway (10). The activity of Shp2, in association with Frs2, is also
essential for maintaining the MAPK pathway activation by interfering with MAPK
phosphatase (278). The MAPK cascade activates different transcription factors that are
essential for differentiation and survival, such as cAMP response element-binding protein
(CREB), Mads box transcription enhancer factor (MEF2), and Elk1 (160, 203).
The majority of the trk receptor signaling studies were developed in PC12 cells, a rat adrenal
pheochromocytoma cell line, which expresses trkA and responds to NGF. Nevertheless,
some studies were also performed on cardiovascular cells. In VSMC genetically modified to
express high level of trkA, NGF induces a prolonged and profound activation of the MAPK
cascade. The activation of this pathway by NGF increases cell migration, but not cell
proliferation (141). In addition, in VSMC, NGF induces the expression of MMP-9 trough
Erk1/2 activation (132). Increased MMP-9 activity contributes to the migratory response of
VSMC. In partial contrast to what is observed in VSMC, NGF treatment of HUVEC causes
a rapid phosphorylation of trkA, thus determining a parallel activation of ERK1/2 and
subsequently an increase in proliferation (34). In primary cultures of rat neonatal
cardiomyocytes, NT-3, via trkC, activated p38MAPK and ERK1/2, thus promoting cell
hypertrophy (128).
2. PLC-γ—In response to receptor kinase activation by NTs, PLC-γ is recruited to a
docking site surrounding phosphorylated Y785 on trkA (or equivalent sites on trkB and
trkC). PLC-γ activation results in the hydrolysis of phosphatidylinositol 4,5-bisphosphate
[PtdIns(4,5)P2] and generates inositol 1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG)
(194), with subsequent stimulation of different PKC isoforms. The proteins activated as a
result of PLC-γ activation include PKC-δ, which is required for NGF-promoted induction of
MEK1 and Erk1/2 (54). The PLC-γ pathway has a role in the migration of VSMC, and NGF
induces a longer activation of this pathway compared with platelet-derived growth factor
(PDGF)-BB (141).
3. PI3K-Akt—The serine-threonine kinase Akt plays a crucial role in the survival activity
of NTs. Insulin receptor substrates (IRS-1 and IRS-2) and Grb-associated binder-1 (Gab-1)
are the main adaptor proteins that mediate the association and activation of PI3K with trk
receptors. Active trk receptors engage Shc, which associates with Grb2. Recruitment of
Gab1 by phosphorylated Grb2 permits subsequent binding and activation of PI3K (280).
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In addition, trk receptor activation results in direct phosphorylation of IRS, which recruits
and activates PI3K (113). Once activated and localized to the membrane, PI3K
phosphorylates phosphoinositol lipids on the D3 position of the inositol ring generating
phosphatidylinositol 3,4,5-trisphosphates [PtdIns(3,4,5)P3]. These lipids serve to recruit
pleckstrin homology (PH) domain-containing enzymes such as Akt and phosphoinositide-
dependent kinase 1 (PDK1) to the plasma membrane. After recruitment to the membrane,
Akt is phosphorylated and consequently activated by PDK (166). In turn, Akt controls the
activities of several proteins through phosphor-ylation. Between the varieties of downstream
Akt substrates, Bad, caspase-9, IkB-kinase, and Foxo transcription factors are involved in
the antiapoptosis effects of Akt. Cell type-specific Akt substrates also exist, such as
endothelial nitric oxide synthase (eNOS), which regulates nitric oxide (NO) biosynthesis in
EC, EPC, and cardiomyocytes (236, 241). Numerous reports show that the PI3K/Akt
signaling pathway is critically involved in EC survival and migration and in angiogenesis
(243). We demonstrated the involvement of Akt in NGF-induced neovascularization and EC
survival in vivo (78). Later, Kim et al. (135) reported that BDNF, via stimulation of trkB
and activation of the PI3K/Akt pathway, mediates the survival of a brain EC line and
induces in vitro angiogenesis (135). A recent study performed in HUVEC demonstrates that
NGF stimulates EC invasion and capillary-like EC tube formation by augmenting MMP-2,
via the PI3K/Akt signaling pathway and activation of the AP-2 transcription factor (200).
Using specific kinase inhibitors, the authors showed that only the PI3K/Akt pathway is
critically involved in NGF-induced MMP-2 increased expression, invasion, and EC tube
formation. In fact, inhibitors of MEK, p38, or Jun NH2-terminal kinase (JNK) did not
effectively suppress these events (200). Moreover, NGF triggers migration of porcine aortic
and choroidal EC in vitro through a PI3K/AKT-involving mechanism (213, 250).
Furthermore, we established that stimulation of rat newborn cardiomyocytes with NGF
induces trkA phosphorylation, followed by Ser-473-phosphorylation and nuclear
translocation of Akt. In response to Akt activation, Forkhead transcription factors Foxo-3a
and Foxo-1 are phosphorylated and excluded from the nucleus, thus resulting in increased
cardiomyocyte survival (36).
B. Transactivation of trk Receptors by G Protein-Coupled Receptor
As previously described for the receptors for epidermal growth factor (EGF) and insulin-like
growth factor I (IGF-I) (59, 162), trk receptors can be transactivated in response to G
protein-coupled receptor (GPCR) signaling. In fact, Lee and co-workers (146, 147) reported
that adenosine promotes neuronal survival through phosphorylation of trk receptors. This
action is antagonized by the trk inhibitor K252 and requires the adenosine receptor A2A
(146, 147). The possibilities that adenosine stimulates NGF production or directly interacts
with trk receptors were discounted (146, 147). Four adenosine receptors have been
characterized (215), and they are all expressed in myocardial and vascular cells, where they
trigger a range of responses, including activation/translocation of PKC, PI3K, and MAPKs
(reviewed in Ref. 204). Trk transactivation by adenosine requires a long kinetics (more than
1–2 h from when adenosine binds the GPCR), and the major parts of the transactivated trk
receptors are found associated with Golgi membranes (214). Moreover, without concomitant
activation of the MAPK cascade, transactivated trkA leads to activation of the PI3K
pathway to promote neuronal survival. Inhibitory experimental approaches reveal that
members of Src family kinases or intracellular calcium might be the mediators of this
transactivation (6, 287). It is also possible that trk receptors are transactivated by additional
GPCRs, either in neurons or in cardiovascular cells. The mechanisms behind trk receptors
transactivation are not completely understood and have not yet been investigated in
cardiovascular cells. Because of the many actions of GPCR on the cardiovascular system
and on progenitor cells, this line of investigation may lead to important findings.
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C. p75NTR Signaling
The function of p75NTR varies considerably depending on the cellular context in which the
receptor is expressed. To date, in vascular cells, p75NTR has only been implicated in
apoptosis (35, 135, 139) and in EC cycle arrest (35). The first evidence of p75NTR-mediated
apoptosis came from Rabizadeh et al. (211), who showed that p75NTR overexpression
induces apoptosis of neural cells in the absence of ligand. We have recently confirmed this
by showing the dramatic apoptotic responses of EC and EPC following transduction with
p75NTR (35). In our hands, p75NTR-transduced HUVEC (but not HUVEC transduced with
control gene) can respond to an exogenously added furin-resistant pro-NGF mutant with a
modest increase in apoptosis (unpublished data), but exogenously added ligand is not
necessary to initiate a robust apoptotic response (35). In contrast, in VSMC genetically
manipulated to express p75NTR and lacking trk receptor expression, treatment with NGF or
NT-3 causes a dose-dependent increase of apoptosis (272). It has been proposed that p75NTR
overexpression produces cell death in a ligand-dependent fashion as well as following ligand
withdrawal. The decision between ligand-dependent or ligand-independent apoptosis might
be related to the cellular contest, as well as the presence of trk receptors and of different
adaptor proteins (reviewed in Ref. 27). The signaling mechanisms used by p75NTR have
remained elusive. The lack of catalytic activity in the cytoplasmic domain of p75NTR
suggests that interacting proteins carry out the signaling of this receptor. Two p75NTR
regions are crucial in protein-protein interaction: the death domain (273) and the
juxtamembrane intracytoplasmatic domain named “chopper” (56). As reviewed by Dempsey
et al. (63) and Vilar et al. (267), several different p75NTR interacting molecules, with and
without catalytic activity, have been identified. Noncatalytic interactors include scaffolding-
and adaptor-like molecules, such as caveolin-1, NADE (p75NTR associated cell death
executor) and TNF receptor-associated factor (TRAF) 4 and 6. Transcription factors
containing zinc-finger domains, such as NT receptor-interacting factor 1/2 (NRIF1/2),
Schwann cell factor 1 (SC-1), and NRAGE (p75NTR-interacting MAGE homolog) can also
bind the p75NTR intracellular domain. P75NTR interactors with catalytic activity include
serine-threonine kinases involved in interleukin and NFκB signaling, such as interleukin-1
receptor-associated kinase (IRAK) and receptor-interacting protein-2 (RIP2), the protein
tyrosine phosphatase Fas-associated phosphatase-1 (FAP-1), and the small GTPase RhoA.
Finally, brain-expressed X-linked 1 (Bex-1) has been recently discovered to interact with
p75NTR in competition with RIP2 (267). How these p75NTR-interacting proteins connect to
downstream signaling pathways and cellular responses has not been extensively elucidated.
Moreover, reports linking adaptor proteins to p75NTR actions on mature or progenitor cells
of the cardiovascular system are still missing, thus calling for significant investigation. In
noncardiovascular cells, ceramide production (67), activation of the transcription factor
NFκB (39), and the c-Jun kinases JNK1-3 (40, 86, 102) have been found downstream to
p75NTR. One hallmark in p75NTR-mediated apoptosis is reportedly the activation of the JNK
signaling cascade (284). Nevertheless, we could never observe increased JNK
phosphorylation in p75NTR-transduced HUVEC undergoing apoptosis (unpublished
observations). Downstream to JNK, described events involved in p75NTR-induced apoptosis
include activation of p53, direct phosphorylation of Bad, release of cytochrome c from
mitochondria, and activation of caspases 9, 6, and 3 (19, 196). P75NTR-induced activation of
JNK cascade was described to be mediated through Rac GTPase (102). Genetic deletion of
TRAF6 prevents p75NTR activation of JNK signaling, thus inhibiting apoptosis in
sympathetic neurons (283). NRIF has been proposed to interact with TRAF6 to induce the
activation of JNK downstream to p75NTR (41, 92). It has been proposed that NRIF nuclear
translocation is necessary for p75NTR-induced cell death. This cytoplasmatic-nuclear
shuttling is modulated by TRAF6-mediated polyubiquitination of NRIF at lysine-63 (88,
156). It was reported that NRIF is ubiquitinated following the γ-secretase cleavage of
p75NTR in response to proapoptotic ligands and that NRIF ubiquitination is essential for its
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nuclear entry (129). TRAF-6 also appears to be involved in p75NTR-mediated NFκB
activation (134). NRAGE interacts with p75NTR to mediate NT-induced cell death through a
mechanism that involves cell cycle arrest, JNK activation, and caspases activation (130).
Bronfman et al. (28) reported that binding of NGF induces p75NTR internalization and the
subsequent association of p75NTR with NRAGE in recycling endosomes. TRAF-6 also
appears to be involved in p75NTR-mediated NFκB activation (134). The possible
interactions of p75NTR with NRIF or TRAF-6 and the activity of NRAGE on cardiovascular
cells have not been investigated, yet.
In noncardiovascular cells, the interaction of p75NTR with NADE has also been shown to
induce apoptosis (179), which is probably modulated by an interaction between NADE and
14 –3-3 protein (136). The effect of p75NTR on survival of noncardiovascular cells is
duplex. In fact, several studies have provided evidence that p75NTR can promote survival
through activation of NFκB (39, 64, 91, 284). This signaling pathway is activated by NGF,
but not BDNF or NT-3 (39), and requires several proteins, including TRAF-6, p62, IRAK,
and RIP2. The complex between TRAF6, IRAK, and p62 is necessary for the
phosphorylation of IKB and subsequent activation of NFκB (165). Finally, p75NTR mediates
sphingomyelin hydrolysis and production of ceramide following NT binding (66). Ceramide
has been shown to promote both apoptotic and prosurvival pathways initiated by p75NTR
activation (248).
SC-1 and Bex-1 have been involved in the action of p75NTR on cell cycle. The transcription
factor SC-1 was the first molecular link between p75NTR and the regulation of cell cycle
identified. Following the binding of NGF to p75NTR, SC-1 translocates to the nucleus and
induces cell cycle arrest (50). A recent study reports that SC1 forms a complex with histone
deacetylases to regulate the levels of cyclins E and B in response to NGF (49). The exact
function of Bex-1 is not clear. It was recently described that, in PC12 cells, Bex1 levels
oscillated during the cell cycle and may contribute to p75NTR-induced cell cycle arrest
(267). Bex-1 looks to mediate p75NTR-induced cell cycle arrest independently to NGF
binding (267). We have found that transduction with p75NTR promotes cycle arrest in
HUVEC in the absence of exogenously added ligand (35). However, NGF is present in the
conditioned culture medium of HUVEC (34). The expression of Bex1 or SC-1 in
cardiovascular cells has not been investigated. If Bex1 and SC-1 are present in p75NTR-
transduced HUVEC, they may play a role in the antiproliferative effect observed in the
absence of added ligands. This hypothesis should be investigated.
Finally, p75NTR also modulates the small GTPase RhoA, a member of the Rho family of
proteins that control the organization of the actin cytoskeleton. In neurons, in the absence of
NTs, p75NTR interacts with RhoA and activates it to inhibit axonal growth. In contrast, NGF
causes dissociation of RhoA from p75NTR, thus blocking RhoA activity and leading to
axonal growth (282). In particular, p75NTR facilitates the release of RhoA from inhibition by
RhoGDI, thus enabling RhoA to be activated. The activated RhoA then interacts with
growth-inhibitory proteins, such as Rho kinase (ROCK) to suppress axonal growth and
regeneration (281).
At this stage, it is essential to understand what are the intracellular interactors of p75NTR in
mature and progenitor cardiovascular cells either in culture or in vivo. This is a prerequisite
toward clarification of the signaling pathways emanating from p75NTR in these cell types.
D. Role of Proteases in p75NTR Activation
Similarly to Notch (62), also p75NTR activation is subject to regulated intramembrane
proteolysis (RIP) (125). The first cleavage of RIP is taken over by the metalloproteinase
ADAM17/TACE that leaves a membrane-bound COOH-terminal fragment (CTF) and
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liberates the extracellular domain (ECD). This first cleavage is permissive for the
subsequent one. The second cleavage is mediated by the γ-secretase and occurs in the
p75NTR-CTF intramembrane region to releases a soluble intracellular domain (ICD) (125). It
has been reported that p75NTR cleavage is stimulated by different activators, such as phorbol
esters, NGF, and pro-NGF (129, 208, 264). Until now, p75NTR cleavage has not been
investigated in cardiovascular cells. It is now clear that the Notch ICD (NICD), which is also
generated by γ-secretase, regulates gene expression by forming transcriptionally active
complexes (239). Although soluble p75NTR-ICD has been localized in the nucleus of
different cells following ligand activation of p75NTR (84, 208), the trancriptional activity of
p75NTR-ICD has not been described.
As reported for other members of TNF-α superfamily, a soluble form of p75NTR has been
detected in various body fluids (286). In particular, using a semiquantitative assay for human
plasma p75NTR, Humpert et al. (116) reported that type 2 diabetic patients had significantly
higher plasma levels of p75NTR-ICD and lower levels of p75NTR-ECD.
Currently, investigations linking p75NTR activation with postreceptor signal transduction are
missing. The only available report describes that ligand-dependent cleavage of the p75NTR is
necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons (129).
Significant work in this field is needed.
E. Cross-Talk Between Neurotrophin Signaling Pathways Activated Through trk and
p75NTR
The presence of p75NTR increases the affinity of NGF for trkA, due to creation of high-
affinity NGF binding-site generation on trkA (108). In turn, several studies suggest that trkA
activation modulates p75NTR signaling. Bamji et al. (12) demonstrated that trkA activation
inhibits BDNF-induced p75NTR-dependent death of sympathetic neurons. Van der Zee et al.
(265) reported that trkA expression is required to counteract the death-inducing effects of
p75NTR. Pathways initiated through trk receptors suppress the stimulation of JNK, the major
proapoptotic-signaling pathway initiated by p75NTR (284). Moreover, p75NTR-dependent
ceramide pathway is blocked by trkA-induced activation of the PI3K pathway (21).
The functional interactions between p75NTR and trk receptor are supported by physical
interaction (20, 228) or facilitated by assembly of multiprotein complexes (9, 10). The
transmembrane protein ARMS (described previously) has been shown to interact with both
p75NTR and trk receptors and to be phosphorylated following trk activation (9, 10).
Caveolin enhances p75NTR-trk complex formation (23). In addition, caveolin overexpression
avoids NGF-induced differentiation of PC12 through a direct inhibition of trk receptor
activity. This inhibition reportedly correlates with an increased ability of NGF to induce
sphingomyelin hydrolysis through p75NTR (22). Interestingly, caveolin-1 is highly expressed
in EC, VSMC, and monocytes (EPC are a subpopulation of monocytes). Depending on the
cell type and the pathological context, caveolin-1 may positively or negatively influence the
development of vascular disease and angiogenesis (reviewed in Ref. 85). Further studies are
necessary to understand the nature of interaction between NT receptors and caveolin in
cardiovascular cells.
Finally, also the p62-TRAF-6-IRAK complex involved in the p75NTR-activated NFkB
pathway functions as a scaffold for association of trk receptors and p75NTR (277).
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IV. ROLE OF NEUROTROPHINS IN CARDIOVASCULAR DEVELOPMENT
NTs and their receptors are expressed by the developing heart and vessels (18, 233).
Seminal studies performed in global knock-out mice implicated NTs in the in utero
development of the heart and the coronary vasculature. In particular, BDNF deficiency
reduces endothelial cell-cell contact in the mouse embryonic heart, thus leading to
intraventricular wall hemorrhage and depressed cardiac contractility (see Fig. 1I) (70).
Similarly, trkB−/− mice show a marked reduction of blood vessel density and increased
number of TUNEL-positive apoptotic EC, predominantly in the subepicardial region of the
developing heart (269). NT-3−/− mice develop abnormalities of the great vessels, including
developmental delay in the primitive myofibril organization of the truncus arteriosus (69,
257). Moreover, genetic deficiency of either NT-3 or trkC impaired cardiac morphogenesis
in mice (see Fig. 1, II and III) (69, 258). Some of these developmental defects appeared as
early as embryonic day 9.5, which is before the onset of cardiac innervation in mice, thus
suggesting the existence of a direct control of NTs on cardiovascular development (257).
Cardiovascular abnormalities are also present in transgenic mice overexpressing a truncated
trkC receptor, which acts as a dominant negative (198). These findings were later expanded
in a chicken model of heart development, which demonstrated that NT-3 and trkC are
coexpressed by developing cardiomyocytes to mediate their proliferation (154). The series
of these developmental studies importantly introduced the concept that NTs have direct
effects on cardiovascular cells, which express trk receptors.
During prenatal development, p75NTR is present in EC and VSMC of large blood vessels, as
demonstrated by immunohistochemistry for p75NTR together with the VSMC marker α-
actin and the EC marker PECAM-1 of wild-type murine embryos (at E11.5) (268). Studies
aimed at understanding the effect of p75NTR deficiency on vascular development were
attempted by von Schack et al. (268), who decided to disrupt exon IV to produce a global
null mouse lacking all p75NTR gene products (p75NTRExonIV−/−). The p75NTRExonIV−/−
mice suffer from significant death at late gestational stages or around birth. The vascular
system of p75NTRExonIV−/− embryos is defective. The dorsal aorta has a thinner wall and
increased lumen diameter. Many p75NTRExonIV−/ − embryos show vascular ruptures and
blood cell leakage (268). Unfortunately, this genetic model was later proven inappropriate,
as it produced a fragment of the p75NTR protein that contains a portion of the extracellular
domain and the transmembrane and intracellular domains. This protein derives from
aberrant expression of a p75NTR mRNA that is initiated 3′ to the inserted pGK-neo cassette
and activates the proapoptotic p75NTR signaling cascades resulting in JNK phosphorylation
and cleavage of pro-caspase-3 (202). There is another global p75NTR knock-out model
available, which was created by deleting p75NTRExonIII (148). This mouse has been used
by many laboratories, but, unfortunately, also p75NTRExonIII−/− mice are not optimal to
understand the involvement of the receptor in cardiovascular development. In fact,
p75NTRExonIII−/− mice maintain expression of an alternatively spliced form of p75NTR (s-
p75NTR) (202, 268).
Mice with global knockout for either trkA or NGF gene can develop to birth, but are smaller
and die early, possibly because of their defective nervous phenotype (58, 246). Their
cardiovascular phenotype has not been studied. By an interesting “reverse conditional” gene
targeting strategy, trkA function was restored specifically in the nervous system to produce
mice lacking trkA in nonneuronal tissues, only. These mice are viable and appear grossly
normal (53); however, their cardiovascular system was not specifically investigated either
during prenatal development or in adulthood. Transgenic mice expressing a neutralizing
antibody against NGF (alphaD11) were also developed. These mice show no gross
phenotype at birth, even if they later develop skeletal muscle dystrophy, apoptosis in the
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spleen, and Alzheimer-like neurodegeneration (37, 226). Also for this model, a targeted
analysis of the cardiovascular system is still missing.
Additional investigations demonstrated the more obvious concept that NTs can influence
cardiovascular development through nerve-mediated actions, as in the case of NGF
transgenic mice, which presented cardiac hyper-trophy due to hyperinnervation (104). The
generation of new animal models lacking or overexpressing the genes for NT receptors in
selected cardiovascular cells should allow elucidating the direct cardiovascular actions of
NTs during development and adulthood.
An alternative interesting approach that can help obtain information on the developmental
actions of candidate molecules is to test their differentiative activity on embryonic and fetal
stem cells. Accordingly, Shmelkov et al. (244) prompted the effect of BDNF on CD133+
stem cells extracted from the human fetal liver. They found that BDNF given alone or
together with VEGF-A is able to address CD133+ stem cells to differentiate toward the
endothelial lineage as well as giving rise to beating cardiomyocytes, which, once
transplanted into the mouse ear, are able to generated electrical action potentials detectable
by electrocardiogram tracing (244). The finding that BDNF promotes differentiation into the
angiomyogenic lineage prompts new investigations aimed to understand the potential of
BDNF and other NTs to improve preparation of cardiomyocytes and EC from embryonic
stem cells and from adult stem cells of different sources, such as the bone marrow or adipose
tissues. It is worth noting that BDNF, NT-3, and NT-4/5 are produced by human embryonic
stem cells (hESC) to mediate their survival by an autocrine mechanism, which engages trk
receptors and initiates the PI3K/Akt pathway without affecting MAPK (209). Moreover, it is
relevant that addition of NTs to hESC cultures induces a 36-fold improvement in their clonal
survival leaving the cells with full conserved developmental potency (209). Furthermore,
when hESC are cultured in the presence of NTs on three-dimensional scaffolds, they can
form vascular structures throughout the engineered tissues (150).
V. DIRECT ACTIONS OF NEUROTROPHINS ON THE ADULT
CARDIOVASCULAR SYSTEM
A. Neurotrophins and Blood Vessel Growth
The development of a complex mature vascular system is a process that requires EC
proliferation and migration as well as the fundamental support of periendothelial cells.
These accessory cells such as pericytes and VSMC interact with EC to form the complex
network of capillaries, arterioles, arteries, and veins. Blood vessels in the embryo form
through vasculogenesis, which is in situ differentiation and maturation of vascular cell
precursor cells that assemble into a vascular network, and angiogenesis (221). The term
angiogenesis was first used to describe the growth of endothelial sprouts from preexisting
postcapillary venules. More recently, this term has been used to generally indicate the
growth and remodeling process of the primitive vascular network into a complex network.
This can involve the enlargement of preexisting vessels which sprout and divide or the
formation of capillaries through transendothelial cell bridges (2, 107) as well as
intussusception, also known as splitting angiogenesis, where the capillary wall extends into
the vascular lumen to split a single vessel in two (65). Angiogenesis and vasculogenesis can
also occur in the adult organism. As reviewed by Carmeliet (38), postnatal angiogenesis
occurs physiologically in the cycling ovary and the placenta. Moreover, angiogenesis is
reactivated during wound healing and repairs and under pathological conditions, such as
cancer, ocular, and inflammatory disorders (38). In 1997, Asahara et al. (11) reported that
adult bone marrow-derived CD34+ hematopoietic progenitor cells, which can be purified
from the mononuclear fraction of peripheral blood cells, could differentiate ex vivo to an
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endothelial phenotype. These cells, which Ashara named “EPC” (endothelial progenitor
cells), showed expression of various endothelial markers and incorporated into neovessels at
sites of ischemia (11). Further studies demonstrated that bone marrow and peripheral blood
CD133+ hematopoietic stem cells also differentiate to EC in vitro (89, 205).
NGF was the first NT to be implicated in postnatal angiogenesis (231). Proliferation,
survival, and migration/invasion of EC are all essential to the angiogenesis process. HUVEC
and pig aortic EC have the mRNA for NGF and its receptors trkA and p75NTR (34, 213),
although the protein expression level of p75NTR is scarce in normally cultured HUVEC (35)
and in capillary EC belonging to healthy murine limb muscle (229). In 2001, Raychaudhuri
et al. (216) first described the proliferative action of NGF on human dermal microvascular
EC, a finding which was later confirmed in HUVEC (34), human choroidal EC (250), and
rat brain EC (177). The proliferative action of NGF on EC is reportedly mediated by Erk
activation downstream of trkA (34). NGF, via trkA, supports EC survival in vitro and in
vivo, an action which is, at least in part, mediated by increased VEGF-A (78, 95, 229). NGF
is a chemoattractant for EC, able to induce migration of human and pig aortic EC (68, 213).
The chemotactic action of NGF on pig aortic EC is reportedly mediated by the simultaneous
activation of the PI3K/Akt and Erk signaling pathways (213). NGF also induces HUVEC
invasion through a collagen I-coated filter, by activating MMP-2 (200). The chorioallantoic
membrane (CAM) of the chicken embryo and the avascular corneal micropocket of rodent
eye are among the primordial assays developed to screen the capacity of molecules to
promote blood vessel growth in vivo (103). NGF induces a dose-dependent angiogenic
response in the rat cornea (240), and it additionally stimulates blood vessel growth in the
chicken and quail CAM (34). NGF-induced CAM neovascularization is partially affected by
anti-VEGF-A antibodies, thus suggesting the involvement of VEGF-A in NGF-induced
angiogenesis (34, 145). In contrast to trk actions, ligand (NGF and pro-NGF)-dependent
activation of p75NTR reportedly induces EC death (135). Moreover, a recent study from our
laboratory described impaired proangiogenic capacity of p75NTR-transduced HUVEC (35).
Figure 2 illustrates enhanced EC apoptosis and defective EC cycle, migration, and capillary-
like structure formation following gene transfer-induced p75NTR expression. Figure 3
summarized the actions and underpinned molecular pathways which activation of trks and
p75NTR stimulates in EC.
Our group was the first to identify the strong angiogenic action exerted by NTs in a mouse
model of limb ischemia, which is instrumental to study the effect of endogenous and
exogenous factors on postischemic reparative neovascularization (78). In this model, as
illustrated by Figure 4, we showed that NGF is an autocrine proangiogenesis factor, which
becomes upregulated together with its trkA receptor following insurgence of ischemia (Fig.
4A) to promote the growth of new capillaries in ischemic muscles. In fact, blockade of
endogenous NGF by a neutralizing antibody disrupts the angiogenesis response to muscular
ischemia (Fig. 4B), while exogenous NGF supplementation to ischemic muscles enhances
the spontaneous formation of capillaries and arterioles in ischemic muscles (Fig. 4, C and D)
and accelerates blood flow recovery (Fig. 4G) (78, 229). NGF actions in ischemic muscles
extend to include antiapoptosis of capillary EC and skeletal myocytes (Fig. 4, E and F) (78,
229). NGF appears to induce angiogenesis through trkA by increasing the expression level
of VEGF-A (33, 78, 101, 230) and possibly VEGF receptors (101) and activating the Akt
intracellular pathways leading to NO production and upregulation of MMP-2 expression
(78, 200, 213). In fact, in the limb ischemia angiogenesis model, NGF-induced angiogenesis
was prevented by a neutralizing antibody for VEGF-A, inhibition of NO synthase (by L-
NAME), or gene transfer with a dominant negative mutant form of Akt (Fig. 4H) (78). As
reported above, also Erk was implicated in NGF-induced EC proliferation and migration,
which are processes potentially utilitarian to angiogenesis. We have more recently found
that NGF gene delivery to the infarcted heart of mice and rats can be used to increase
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capillary density and inhibit EC apoptosis in the peri-infarct area (unpublished data), which
may have important therapeutic implications. Moreover, NGF promotes angiogenesis in
healing cutaneous wounds, thus favoring cicatrisation (95).
Some of the angiogenesis-related actions of NGF have been later proved to be shared by
BDNF. In 2000, Nakahashi et al. (182) found BDNF mRNA and protein in HUVEC. Kim et
al. (135) confirmed BDNF expression by EC and additionally showed that EC express trkB
and that the level of BDNF transcript is upregulated by hypoxia in EC, a feature which is
compatible with a proangiogenesis action of the BDNF. The hypoxia-mediated regulation of
BDNF in EC was confirmed by Wang et al. (270) using a mouse brain microvascular EC
line (bEnd.3 cells). BEnd.3 cells respond to either sustained or intermittent hypoxia with
increased production and release of BDNF in the culture medium. Endogenous BDNF
promotes EC survival, while exogenously added recombinant protein stimulates in vitro
angiogenesis, via PI3K/Akt (135). Similarly, to NGF, also BDNF, via trkB, reportedly
upregulates VEGF-A expression level. According to Nakamura et al. (183), this action is
induced by PI3K and hypoxia-inducible factor 1 alpha (HIF-1α). In turn, VEGF-A can
upregulate BDNF mRNA level, as observed in myometrial microvascular EC (276).
Inhibition of VEGF receptor 2 significantly decreases BDNF expression in brain EC (47).
Given the knowledge that VEGF-A, via Akt phosphorylation of eNOS, stimulates NO
production from EC (1, 87) and that NO reportedly upregulates BDNF (46), it is possible
that eNOS-derived NO is involved in the VEGF-A-induced increase in BDNF. Kermani et
al. (131) tested the potential of angiogenesis gene therapy with BDNF in the ischemic limb
mouse model. Similar to what was already observed for NGF, BDNF expression is
upregulated in ischemic limb muscles to induce phosphorylation of vascular trkB. Gene
transfer-mediated BDNF overexpression increases capillary density of ischemic muscle,
thus accelerating blood flow recovery (131). Interestingly, intravenous injection of an
adenovirus carrying the BDNF gene induces the mobilization of Sca-1+CD11b+
hematopoietic progenitor cells in the peripheral blood of mice. The finding, which is in line
with the presence of trkB and other NT family components in the bone marrow (142), was
confirmed in vitro by studying the migration toward BDNF of total bone marrow cells. In
this system, BDNF proved to predominantly attract MOMA-2+ and Sca-1+ cells. In line,
ischemic muscle transduced with BDNF showed increased infiltration of MOMA-2+CD45+
cells (131). The report by Kermani et al. (131) was the first to suggest a supportive effect of
NTs on postnatal vasculogenesis. However, a more exhaustive definition of adult progenitor
cell populations responding to BDNF and NTs is necessary. In addition, Kermani and
colleagues (78, 131) did not demonstrate that increased circulating MOMA-2+ and Sca-1+
cells and enhanced infiltration of MOMA-2+CD45+ cells effectively contribute to BDNF-
induced neovascularization of ischemic limb muscles. Unlike NGF, the proangiogenic
actions of BDNF are not hampered by neutralizing VEGF. In addition, BDNF increases
capillarization, but it has no effect on arterioles or small arteries, although this latter finding
is apparently difficult to reconcile with BDNF-induced improved blood flow recovery (78,
131). Another difference from NGF is that BDNF does not induce angiogenesis in the
corneal pocket model, which may be explained with the absence of trkB in EC belonging to
this district (131, 240). Rather, BDNF induces angiogenesis in both the Matrigel plug and
the mouse ear models, with its responses being comparable to those elicited by VEGF-A
(131). NT-4/5, which is an additional ligand of trkB, is also able to promote angiogenesis in
the Matrigel model (131). Recent findings from our laboratory suggest that BDNF gene
transfer promotes neovascularization of the peri-infarct myocardium (unpublished data). Our
data are in line with the report that BDNF potentiates basic fibroblast growth factor (bFGF)-
induced angiogenesis and improves cardiac function following myocardial infarct (157).
Moreover, BDNF induces blood vessel growth in transected adult rat thoracic spinal cord, as
demonstrated when using BDNF to impregnate freeze-dried poly(D,L-lactic acid)
macroporous guidance scaffolds (201). It is also possible, even if not yet demonstrated, that
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BDNF plays a role in brain angiogenesis induced by physical exercise. In fact, the levels of
brain BDNF and VEGF-A increase and angiogenesis develops in the brain of exercising
mice (55). It has been demonstrated that blocking VEGF-A inhibits exercise-induced brain
angiogenesis (55). As, out of the brain, BDNF is able to upregulate VEGF-A and vice versa
(183, 276), the involvement of BDNF in brain angiogenesis is plausible.
The main receptor for NT-3, trkC, is not expressed by HUVEC, which are the most popular
model of EC used by angiogenesis laboratories. This fact possibly explains why NT-3 has
not been investigated as a potential angiogenesis mediator. Nevertheless, trkC is highly
expressed by human veins and mouse capillary EC (unpublished data). Unpublished data
from our laboratory show that adenovirus-mediated NT-3 gene transfer to murine ischemic
hindlimbs stimulates the proliferation of capillary EC, thus increasing capillary density
(unpublished data). These findings apparently contradict a previous investigation which
proved NT-3 to inhibit the mitogenic activity of rat brain EC (255). Gene therapy with NT-3
can promote blood flow recovery to the ischemic foot (unpublished data). Western blot
analyses of NT-3-transduced muscles revealed increased levels of phosphorylated trkC,
Ser-473-phosphorylated Akt, and Ser-1177-phosphorylated eNOS. Increased eNOS protein
level and NO production following stimulation with NT-3 were also reported in rat brain EC
(255). In contrast to what was found for NGF, the content of VEGF-A mRNA or protein is
unchanged by overexpressing NT-3 (unpublished data). The scheme in Figure 5 summarizes
the potential of NTs/trks to induce blood vessel growth by angiogenesis and vasculogenesis.
B. Neurotrophins and Vascular Smooth Muscle Cell Control
NGF, BDNF, and NT-3 are expressed in the wall of the aorta and pulmonary artery of
embryonic and postnatal rat. The level of NT-3 in blood vessels is relatively constant from
the embryonic to adult stage, while levels of BDNF increase and those of NGF decrease
(233). Other studies show discrepancies of results about BDNF expression, reporting only
faint BDNF mRNA expression in the heart (109, 164, 259).
Cultured VSMC express NTs and their receptors and secrete NTs in a regulated manner (71,
184, 185, 261). VSMC possess proprotein convertases (PC), such as furin, PC5, and PC7,
which are deputed to the maturation of pro-NTs in their active form (249). NGF does not
stimulate VSMC proliferation, but it is a potent chemotactic agent for human aortic VSMC
(71). NGF-induced VSMC migration is mediated by PI3K and Akt, as it can be blocked by
either LY294002 or wortmannin (141). The NGF/trkA receptor signal, via Shc/MAPK
pathway, induces MMP-9 expression in primary rat aortic VSMC and in a VSMC line
genetically manipulated to express trkA. MMP-9 may favor VSMC migration and invasion
(132). Stimulation with NGF, NT-3 and, to a less extent, BDNF of p75NTR-expressing
VSMC promotes apoptotic death (272). The role of trkA in VSMC apoptosis is still
controversial (26, 272).
Figure 6 illustrates the actions and underpinned molecular pathways that could be stimulate
by NTs in VSMC.
C. Actions of Neurotrophins on Cardiac Myocytes
The first evidence of secretion of neurotrophic factors by heart cells was obtained in 1979,
when Eberdal et al. (73) showed that heart explants support neurite extension from sensory
neurons in vitro. All NTs are expressed by the mammalian heart, as demonstrated by
different techniques (112, 164, 238, 259). Truncated form of trkB and trkC receptors have
also been reported in human or rat hearts with Northern blotting or RNase protection assay
(242, 260).
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We have recently identified that NGF is an autocrine prosurvival factor for cardiomyocytes
(36). Rat neonatal cardiomyocytes express and release NGF (36, 117) and possess trkA (36)
(Fig. 7). Moreover, cardiomyocytes undergo apoptosis when treated with a neutralizing
antibody for NGF or the trkA inhibitor K252a (Fig. 7B). Furthermore, NGF expression in
cultured cardiomyocytes increases following either hypoxia/reoxygenation (H/R) or
incubation with high ANG II levels, two conditions inducing cardiomyocyte apoptosis.
When, under each of those conditions, the NGF/trk receptor signaling is inhibited, apoptosis
is dramatically augmented, thus reinforcing the idea of an antiapoptotic role for this NT
(36). Increased NGF level obtained by either gene transfer or supplementation with a NGF
recombinant protein protects neonatal and adult cardiomyocytes from apoptosis induced by
either H/R (Fig. 7C) or ANG II (36). The prosurvival signal of NGF in cardiac myocytes
encompasses Akt phosphorylation and the nuclear/cytosolic shuttling of Akt and Forkhead
transcription factors Foxo-3a and Foxo-1 (36). Finally, in a rat model of myocardial
infarction, NGF gene transfer supports cardiomyocytes survival (Fig. 7D) (36). Akt
promotes both survival and (physiological and pathological) hypertrophy of cardiomyocytes
(reviewed in Ref. 42). Anversa and Sussmann (42) proposed the theory that extranuclear Akt
plays the double role of promoting survival and growth by acting on several redundant
downstream targets, including Bad and glycogen synthase kinase-3, whereas nuclear Akt
combats apoptosis without interfering with the control of cell size. Indeed, the knowledge
that Foxo is a nuclear target of Akt (274) and that Foxo-3a and Foxo-1 are negative
regulators of myocyte hypertrophy (187, 245) requires a new look at the role of nuclear Akt
in growth. Although the impact of NGF on cardiomyocyte size was not the objective of our
recent study (36), we consider this issue of high relevance. Interestingly, NT-3, via trkC,
reportedly promotes cardiomyocyte hypertrophy, possibly by acting on MAPK (128). We
found that also trkB is expressed by rat neonatal cardiomyocytes (unpublished results), thus
suggesting that BDNF may trigger responses in these cells. Further investigations are needed
to improve our understanding of the full range of NT actions on the developing and adult
cardiomyocytes.
Figure 8 illustrates the actions and signaling pathways emanating from trk receptors in the
cardiomyocyte.
VI. NEUROTROPHINS IN CARDIOVASCULAR PATHOLOGY
A. Neurotrophins and Cancer Angiogenesis
Angiogenesis is essential for tumor development and metastasis. To initiate angiogenesis,
tumor cells make an angiogenic switch by perturbing the local balance of pro- and
antiangiogenesis factors and proteases (83). Being strong promoters of angiogenesis and
able to activate VEGF-A and metalloproteases, NTs may contribute to the growth and
diffusion of cancers (17, 72, 121, 188), even if this hypothesis has not been exhaustively
validated, yet. It may be interesting to remember that the trk gene has originally been cloned
as an oncogene fused with the tropomyosin gene in the extracellular domain conferring
constitutive activation of its tyrosine kinase activity to induce continuous cell proliferation
(14, 180). Surprisingly, this gene was discovered to code for a high-affinity receptor for
NGF (180). Trk receptors regulate growth, differentiation, and survival of tumors with
neuronal origin, such as neuroblastoma and medulloblastoma (180). High expression of
BDNF and trkB is considered a poor prognosis marker in neuroblastoma, one of the most
common pediatric neoplasms (7, 169). Furthermore, trkB activation by BDNF, via HIF-1α
and PI3K/mTOR, induces VEGF-A in neuroblastoma cells (183). In contrast, high
expression of trkA is known to be a marker of good prognosis in the same tumor type (181).
This discrepancy was explained in terms of the dependence of trkA-expressing
neuroblastoma cells on NGF, which, when present in abundance, pushes them to mature or,
when NGF is too low, to die (180). However, it was also shown that NGF-mediated
CAPORALI and EMANUELI Page 16
Physiol Rev. Author manuscript; available in PMC 2010 March 11.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
activation of trkA decreases the content of proangiogenesis factors in the conditioned
medium of neuroblastoma cells (74). Opposite results to neuroblastoma were found for
medullary thyroid carcinoma (MTC). Compared with control cells, trkB-overexpressing
MTC cells produce less VEGF-A in vitro and develop less and smaller cancers when
implanted in mice, while trkA-overexpressing MTC cells give more VEGF-A and promote
tumorigenesis and cancer growth in vivo (174).
Moreover, NGF is produced by hepatocellular carcinoma cells, and trkA was found
expressed in the vascular walls of tumor-associated arteries, thus suggesting that NGF/trkA
signaling may participate in cancer angiogenesis (137). Further support for this hypothesis
comes from the finding that, in ovarian carcinoma, activated trkA is present on the EC
membrane, both inside the tumor and in its vicinity (60). NGF is also produced by human
melanomas (170), and both NT-3 and trkC are expressed by EC in or around human gliomas
(32). In addition, malignant glioma-released NT-3 has the capacity to attract bone marrow-
derived stroma cell (24), which may have implications for tumor vasculogenesis.
All these findings suggest the possibility that NTs can control cancer angiogenesis and
consequently the growth and diffusion of primary tumors. However, a systemic evaluation
of this concept was never developed, and cause-effect studies are especially important at this
stage.
B. Neurotrophins and Angiogenesis Associated With Chronic Inflammation
Angiogenesis is intrinsic to psoriasis and arthritis. Psoriasis is a chronic inflammatory skin
disorder characterized by accelerated proliferation and altered differentiation of
keratinocytes and microvessels undergoing angiogenesis (57). NGF is produced by healthy
and psoriatic epidermal keratinocytes and fibroblasts (4, 218), as well as by dermal
microvascular EC (216). In a murine model of cutaneous pressure ulcers, NGF promotes
angiogenesis (95), thus accelerating wound healing (95). A similar wound closure effect by
NGF has been reported in full-thickness skin wounds in mice (168). In a SCID mouse-
human skin chimeras xenograft model, NGF was seen to stimulate EC proliferation and
induction of the intercellular adhesion molecule (ICAM-1) on EC (217, 219). In the same
experimental model, either NGF neutralization or inhibition of trk receptors by K252a
improved psoriasis (219). In addition, NGF upregulates the expression levels of substance P
(155), which is a strong proangiogenesis inducer (285) involved in psoriasis (219). These
findings, which need to be confirmed and expanded in future studies, suggest a role of NGF
in psoriasis-associated angiogenesis. To the best of our knowledge, no report linking other
NTs or their receptors to psoriasis are currently available.
Angiogenesis in the synovial membrane is considered an important early step in the
pathogenesis and progression of inflammatory arthritis, particularly rheumatoid arthritis.
Angiogenesis is required for the development of the rheumatoid pannus, which then leads to
extensive synovial inflammation and joint destruction (133, 254). Consequently, it is
relevant that NTs and their receptors are present at both mRNA and protein levels in
inflamed peripheral joints of rheumatoid arthritis and spondyloarthritis patients (220). Both
trkA and p75NTR are expressed in the endothelium of synovial tissue biopsy specimens
obtained from clinically affected knee joints of patients with rheumatoid arthritis,
spondyloarthritis, and osteoarthritis (220). Notably, NGF appears to be elevated in the
synovial fluids of rheumatoid arthritis patients in comparisons with normal human synovial
fluids (100). Investigations addressing the causative role of NTs in arthritis-linked
angiogenesis have not been carried out.
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C. Neurotrophins in Cardiovascular Inflammation, Atherosclerosis, and Vascular Wall
Remodeling
Atherosclerosis is a complex, chronic inflammatory process of the arterial wall that involves
the recruitment and activation of cells in a developing intimal lesion. Among the events
triggering this process is the EC activation by inflammatory cytokines and oxidized
lipoproteins, followed by the increased adhesion of blood-circulating monocytes to the
activated endothelium and the migration of VSMC into a developing neointima. Then, lipid
accumulation and modulation of vascular cell phenotypes by extracellular matrix proteins
(especially metalloproteases) stimulate the development of an atherosclerotic plaque (140),
which progressively obstructs the vascular lumen, thus reducing blood flow. The attempts to
reestablish lumen patency by percutaneous transluminal angioplasty can result in the
damage of the EC and the vascular internal elastic lamina, which in turn activates the shift of
VSMC from a contractile to a synthetic phenotype and the VSMC migration to the lumen.
This process culminates in neointima formation and restenosis of the vessel (186). Figure 9
illustrates the possible role played by NTs in neointima formation. Human and rat VSMC
express NTs, p75NTR, and trk receptors in vivo and in culture (71, 141, 272). The expression
levels of NGF, BDNF, trkA, and trkB are dramatically upregulated by arterial balloon injury
in rats, and increased levels persist during neointima formation (71). BDNF, NT-3, NT-4/5,
trkB, trkC, and p75NTR were also found expressed in VSMC of human atherosclerotic
lesions (71, 139), thus suggesting an implication of NTs in regulating VSMC response to
vascular injury (71). This hypothesis is further supported by the knowledge that NGF
promotes VSMC migration, via trkA (71, 141), while p75NTR stimulates VSMC apoptosis
(139, 272). Furthermore, in VSMC, NGF induces the expression of the gelatinase MMP-9
(132), which has prominent activity against basement membrane components and becomes
rapidly activated following mechanical injury (186). MMPs are major players in intimal
thickening and atherosclerotic plaque development and rupture (186). Kraemer et al. (140)
crossed trkB+/− with the atherosclerosis apolipoprotein E gene knock out mouse model
(ApoE−/−) to find that reduction in trkB signaling slows the appearance of lipid deposition
and neointima formation in mice fed with a proatherogenic diet (140). Unexpectedly,
MMP-9 levels were identical in the vascular lesions of trkB+/− ApoE−/− and trkB+/+
ApoE−/− mice (140). However, other matrix proteases might be regulated in their expression
and activity by trkB. Bone marrow-derived inflammatory cells are less in vascular lesion
developed by trkB+/− ApoE−/− mice compared with trkB+/+ ApoE−/− mice. This difference
could not be explained with the reduced trkB presence in bone marrow cells. In fact, results
of experiments with bone marrow cross-transplantation between trkB+/− ApoE−/− and
trkB+/+ ApoE−/− mice disclaimed the importance of trkB presence in bone marrow for
infiltration of inflammatory cells in atherosclerotic lesions (140). The latter finding is in
apparent contradiction with another report of the same group, showing a prominent role of
BDNF in stimulating mobilization of trkB+Sca-1+MOMA2+ from the bone marrow to
engraft in tissue expressing high level of BDNF (131). We should not forget that BDNF/
trkB activates an important prosurvival signaling for EC (135), and the integrity of luminar
EC is fundamental to avoid adhesion of monocytes and to maintain VSMC in a contractile
rather than proliferative status. Therefore, it is possible that the role of trkB in vascular wall
remodeling and atherosclerosis is more complex. New models separately targeting trkB
expression in EC, VSMC, and monocytes may provide more substantial information.
In support of a proinflammatory effect of trkB is a phage-display study, which identified
increased trkB expression in the aging rodent heart (31). This was associated with functional
studies revealing that age-associated alterations in the cardiac BDNF/trkB signaling enhance
inflammation and increase myocardial injury after myocardial infarction in the aging heart
(31). A role for BDNF in the pathogenesis of coronary artery disease has been also proposed
(76). According to Ejiri et al. (76), BDNF derives mainly from diseased coronary arteries
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and contributes to plaque instability through enhancing local NADPH activity and
superoxide production. These assumptions derived from finding higher BDNF
concentrations in the EDTA-containing plasma of the coronary sinus than in the aortic root
of patients with acute coronary syndrome (76). However, high levels of BDNF are stored in
human platelets. Increased blood flow velocity and shear stress in the presence of significant
narrowing of epicardial coronary arteries lead to platelet activation, and this may justify the
BDNF released in the circulation. Therefore, it is possible that BDNF is not released by
diseased vessels, but by activated platelets (158). It is also possible that, since BDNF is a
prosurvival factor for EC, diseased vessels increase its production and release for their self-
protection.
D. p75NTR-Induced Impairment in Postischemic Reparative Neovascularization in Diabetes
Type 1 diabetes downregulates the content of NGF and trkA in ischemic skeletal muscles
and concomitantly induces p75NTR expression in capillary EC (35, 36, 229) (see Fig. 10A).
Recent data from our group provide evidence that p75NTR is responsible for diabetes-
induced impairment in neovascularization of ischemic limb muscles. In fact, when diabetic
mice were treated with an adenovirus carrying a dominant negative p75NTR mutant form in
their ischemic limbs, the postischemic angiogenesis process and blood perfusion recovery
were normalized to levels similar to what was observed in normoglycemic mice (see Fig.
10B) (35). Interestingly, NGF supplementation, rather than initiating apoptosis of diabetic
EC via p75NTR, downregulates p75NTR expression, by a mechanism which has not yet not
been clarified, and promotes EC survival and vascular regeneration (95, 229).
VII. NEUROTROPHIN-BASED THERAPEUTIC PERSPECTIVES
As illustrated above, NTs can promote reparative neovascularization. Therefore, NTs could
be of therapeutic value for ischemic diseases, such as peripheral ischemia and myocardial
infarct, which would benefit from strategies able to improve blood flow. Moreover, because
of their capacity to promote neuroprotection and neurogenesis together with cardiovascular
protection and angiogenesis, we consider NTs particularly appealing for treatment of
conditions in which both microangiopathy and neuropathy are pathogenetically involved.
This is the case, for example, of the diabetic foot. Loss of nociception, axon-reflex
vasodilation, and microangiopathy leading to ischemia contribute to cutaneous ulceration in
diabetic subjects. Interestingly, NGF, which is trophic to sensory and sympathetic fibers, is
reduced in diabetic nerves, and endogenous NGF deprivation results in hypoalgesia (3, 5).
NGF, BDNF, and NT-3 have all been found to be reduced in early diabetic neuropathy skin
(3). Recombinant NGF has been tested in a clinical trial of diabetic polyneuropathy,
showing promise at the phase II level (8). Unfortunately, the only phase III trial attempted to
date showed negative results, which stopped the investigation, even when the trial design
had been questioned (8). Nevertheless, cases of diabetic patients with limb ulcers
unresponsive to conventional therapies responding positively to topical application of NGF
have been described (90). Moreover, NGF-based therapy proved beneficial for stimulating
angiogenesis and healing of skin wounds in diabetic mice (95). NGF additionally showed
the potential to cure several forms of skin ulcers in humans, such as foot pressure ulcers
(144), ischemic skin lesion of the foot in a child with Crush syndrome (48), and chronic
vasculitic ulcers associated with rheumatoid arthritis (262). In all these cases, even if it was
not specifically assessed, it is possible that NGF-induced neoangiogenesis may have
contributed to the healing action of the NT. NGF additionally proved its ability to treat
neurotrophic (25, 143) and herpetic corneal ulcer (171).
The diabetic heart is also expected to benefit from NGF supplementation. In fact, the
diabetic heart suffers from exaggerated apoptosis of cardiomyocytes and vascular cells
(223), which NGF is able to combat (78, 229). Furthermore, a main cause of sudden death in
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diabetes is silent myocardial ischemia, caused by cardiac sensory nerve impairment. Ieda et
al. (118) interestingly demonstrated that NGF is critical for cardiac sensory innervation and
that NGF gene therapy to the heart rescues neuropathy in diabetic rats.
Another clinical condition in which we foresee a particular potential for NT-based therapies
is erectile dysfunction, where neurogenic and vasculogenic causes are both involved.
Diabetes and hypercholesterolemia are possible causes of erectile dysfunctions. NTs and
receptors are expressed by penis-projecting neurons of the major pelvic ganglion as well as
by penile sensory neurons, which are all involved in erections (110). Angiogenesis gene
therapy of the corpus cavernous with VEGF-A and angiopoietin-1 has been recently shown
to improve erectile function in hypercholesterolemic rats (227), thus anticipating the
possibility that proangiogenic NTs may be ideal drug candidates for treating this disabling
condition. In agreement, NT-3 delivery to the cavernous nerve of type 1 diabetic rats
significantly enhances intracavernous pressure (16), which may have been partially due to
neoangiogenesis under the stimulation of secreted NT-3. Moreover, combined VEGF-A and
BDNF improved the erectile response in a nerve-crush rat model (114) and in erectile
dysfunction induced by hyperlipidemia (93). Also in these cases, the proangiogenesis action
of NTs may have played a role.
NTs are not considered good drug candidates, because of their poor pharmacokinetic
behavior and, in case the target is the brain, lack passage across the blood-brain barrier.
Moreover, NTs, even if with lower affinity than pro-NTs, can still activate the proapoptotic
p75NTR (153, 232). Some of these considerations may in part justify the partial
disappointment with the trial using recombinant NGF in diabetic neuropathy (8). Apart from
gene therapy or cell-based gene delivery, alternative strategies to the use of NT proteins may
consist of using small molecule activators of trks. Recently, cell-permeable small
compounds able to activate trkA (but not p75NTR) in the absence of NGF have been
developed starting from the screening of libraries of asterriquinones and mono-indolyl-
quinones using a 96-well enzyme-linked immunosorbant assay that detects phosphorylated
trkA (153). By similar or alternative approaches, small molecule agonists for trkB and trkC
could be developed for antiapoptosis and proangiogenesis therapies. The same experimental
platform could be also exploited to develop antagonist compounds able to block NT-induced
activation of trks. In this case, the obvious therapeutic target would be represented by
pathological angiogenesis associated with naturopathic pain and inflammation, such as
arthritis and psoriasis, or cancer. In addition, the team led by Longo and Massa (159) has
prepared NGF small molecule mimetics, able to act selectively at p75NTR or trkA receptors
and activate partially distinct patterns of intracellular signaling cascades, compared with
those activated by NGF. Of these molecules, the ones selectively activating trkA may
deserve to be tested for the ability to promote angiogenesis in ischemic tissues. Moreover,
trk function can also be improved by inhibition of protein-tyrosine phosphatase (279).
Conversely, small molecules able to sequestrate NTs, thus impeding interaction with their
receptors, could have a scope in pathological angiogenesis. This may be the case for the
recombinant domain 5 of trkA (trkAd5), which binds to NGF, thus inhibiting NGF action
(61). TrkAd5 showed a therapeutic potential in preclinical models of inflammatory pain and
asthma (61). In general, drugs able to block trk signaling at receptorial or postreceptorial
level might have a role in inhibiting angiogenesis.
VIII. SUMMARY AND PERSPECTIVES
In this review, we have described the components of the NTs family, showing that mature
NTs and proforms of NTs can bind, with different affinities, to two receptor types: the
tropomyosin kinase receptors (trks) and the p75NTR. We have reported expression of both
types of receptors by cardiovascular cells, which is an essential prerequisite for direct
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cardiovascular actions of NTs. We have also described the signaling mechanisms
downstream of NT receptors. The first hints of the existence of direct cardiovascular actions
of NTs stemmed from pioneering work on development of mice with global gene knockout
for NT-3, trkC, BDNF, and trkB. These studies, together with more recent data on the role
of NTs in cardiovascular development and stem cell differentiation into the angiomyogenic
lineage, have been extensively described by this review. Next, we have illustrated the roles
of NTs in cardiovascular physiology during adulthood. In developing and adult organisms,
endogenous NTs control the growth and maintenance of blood vessels as well as the survival
of cardiac myocytes. On the other side, NTs can also participate in pathological events, such
as cancer angiogenesis and angiogenesis associated with other situations of chronic
inflammation (psoriasis, arthritis, etc.). NTs also contribute to athersclerosis and vascular
wall remodeling following intraluminar vascular injury or changes in blood flow. Recent
data from our laboratory provide novel evidence that p75NTR induces EC apoptosis and
cycle arrest and contributes to diabetes-induced impairment in reparative angiogenesis
following induction of peripheral ischemia (35). We have finally discussed potential disease
targets that can benefit from therapies based on NTs, NT-mimetic, and enhancers of trk
receptor actions to promote cardiovascular protection or, vice versa, trk inhibition or
antagonism to arrest pathological angiogenesis.
We hope that this review will serve to encourage additional research in the cardiovascular
actions of NTs.
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FIG. 1.
Genetic deficiency of brain-derived neurotrophic factor (BDNF), neurotropin-3 (NT-3), or
tropomyosin-related kinase receptor C (trKC) causes cardiac and vascular defects in the
developing mammalian heart. I: BDNF−/− neonate mice exhibit ventricular wall
hemorrhage. Histological analyses of BDNF+/+ (A, C, and E) or BDNF−/− (B, D, and F–H)
littermates killed at P0. Hematoxylin and eosin-stained sections reveal hemorrhage in the
epicardial third of both right and left ventricular walls of BDNF−/− neonates (B and D,
arrowheads) and an atrial septal defect (B). Pulmonary hemorrhage is detectable in BDNF−/−
(F) but not BDNF+/+ littermates (E). Hemorrhage was not detectable in other organs, such as
kidneys (G) as well as skin and spinal cord (H). Ra and la, right and left atria; rv and lv,
right and left ventricles; asd, atrial septal defect; s, skin; m, skeletal muscle; vb, vertebral
body; sc, thoracic spinal cord. Scale bars, 150 μm (A and B), 50 μm (C and D), 100 μm (E–
H). [From Donovan et al. (70), with permission from Development.] II: schematic
representation of cardiac abnormalities in NT-3−/− neonate mice. Schematic representations
of normal cardiac anatomy(A), the NT-3−/− mutant heart (B), the aorta (AO), ductus
arteriousus (DA), right and left atrium (RA, LA), right and left ventricle (RV, LV), tricuspis
(TV), and mitral (MV) valve are indicated. [From Donovan et al. (69), reprinted by
permission from Macmillan Publishers Ltd.] III: table showing heart abnormalities in
trkC−/− mice. [Adapted from Tessarollo et al. (258).]
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FIG. 2.
The angiogenic potential of endothelial cells is impaired by p75NTR. A: human umbilical
vein endothelial cells (HUVEC) were infected with different concentrations of an adenoviral
vector carrying human the p75NTR gene (Ad.p75NTR) or with Ad.Null (control). After 48 h,
cell lysates were collected and subjected to Western blotting with antibodies to p75NTR, the
apoptosis marker cleaved caspase-3, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (loading control). These analyses provide evidence that p75NTR expression
induces EC apoptosis. B: apoptotic nuclei of transduced HUVEC were detected by the
TUNEL assay. Fluorescent images are representative of apoptosis rate in Null-HUVEC and
p75NTR-HUVEC. Original magnification: ×400; scale bar: 40 μm. Green fluorescence:
TUNEL-positive nuclei; blue fluorescence: all the nuclei. Arrows point to TUNEL-positive
nuclei. Bar graphs quantify apoptosis, which is expressed as percentage of TUNEL-positive
nuclei to total nuclei. Data are presented as means ± SE. *P < 0.05 and **P < 0.001 vs.
Ad.Null. C: HUVEC were transduced with p75NTR or Null and syncronized by serum
starvation. Following the release from cycle arrest, the cell cycle progression was assessed
by flow cytometric analysis, at the indicated time points. The percentage of cells in G1, S,
and G2 phases is indicated in figures. These analyses showed defective cell cycle
progression in p75NTR-HUVEC. D: migration toward the chemoattractant stroma derived
factor-1 (SDF-1; 100 ng/ml) is reduced for p75NTR-HUVEC compared with Null-HUVEC.
In bar graph, values are means ± SE. #P < 0.05 vs. Ad.Null combined with PBS, *P < 0. 05
vs. Ad.Null combined with SDF-1. Top panels show representative microscopic fields
(original magnification: ×100; scale bar: 100 μm). E: the potential of HUVEC to form
vessel-like structures on Matrigel is impaired by p75NTR transduction. Images (original
magnification: ×100; scale bar: 100 μm) show the time course (up to 24 h from cell seeding)
of cell organization on Matrigel. In bar graphs, the quantification of EC tube network
formation at 24 h from seeding is expressed as the number of intersecting points of tubular
structures for microscopic field (left) as well as the percent of microscopic field area
covered by connected tubular structures (right). Values are means ± SE. **P < 0.01 vs.
Ad.Null. [From Caporali et al. (35).]
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FIG. 3.
Neurotrophin actions on the endothelial cell. Under basal conditions, the neurotrophin
receptor trkA and trkB (and, in some tissues, also trkC) are expressed by EC. Trk receptor
engagement by mature NTs initiates two major signaling pathways, Erk MAPK and IP3K/
Akt. Nerve growth factor (NGF) treatment of EC causes a rapid phosphorylation of trkA,
determining a parallel activation of ERK1/2 and a subsequent increase in EC proliferation
and migration. Activation of the PI3K/Akt signaling pathway promotes EC survival.
Moreover, via the PI3K/Akt, NGF stimulates EC invasion and cord formation by
augmenting MMP-2. NGF, via trkA, supports EC survival in vitro and in vivo, an action
which is, at least in part, mediated by increased VEGF-A. BDNF, via trkB, also supports EC
survival. Under basal conditions, the p75NTR is scarcely expressed by EC. Following
p75NTR induction or transduction, the receptor triggers EC apoptosis and inhibits EC cell
cycling through mechanisms that may be dependent or not from ligand (mature NT and pro-
NGF) activation.
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FIG. 4.
NGF promotes angiogenesis and arteriogenesis in ischemic hindlimbs. A: time course of
NGF content in adductor muscles following induction of hindlimb ischemia. Values are
means ± SE (n = 4 for each time point). *P < 0.05 vs time 0. B: endogenous NGF promotes
angiogenesis in ischemic limb muscles. Twenty-one days from ischemia induction, control
IgG-treated mice (n = 6) showed higher capillary density in ischemic adductors (I) than in
contralateral normoperfused muscles (C). The capillary response to ischemia was prevented
in mice given a NGF-neutralizing antibody (anti-NGF Ab, n = 8). Values are means ± SE.
*P < 0.05 vs. contralaterals. §P < 0.05 vs IgG. C and D: supplementation of NGF to
ischemic limb muscles promotes angiogenesis and increases arteriole numbers. Local daily
injections of NGF (full columns) or vehicle (V, dotted columns) in ischemic muscles were
repeated over 5 or 14 days, starting from the day of ischemia induction. Capillary (C) and
arteriole (D) density was evaluated 14 days thereafter. Microvascular density of untouched
adductors (open column) is shown as a reference. Neovascularization was potentiated at
arteriole and capillary level by 14-day NGF treatment. Five days of treatment exerted an
effect on arteriole growth only. Values are means ± SE. *P < 0.05 vs. controls. §P < 0.05 vs.
V; +P < 0.05 vs. 5-day treatment. E and F: supplementation of NGF reduces apoptosis of
endothelial cells and skeletal myocytes in ischemic adductor muscles. NGF or vehicle was
intramuscularly injected every day starting on the day of femoral artery excision. Muscles
were harvested 5 days later. Apoptosis found at the level of capillary endothelial cells (ECs)
and skeletal myocytes was expressed as the number of TUNEL-positive cells per 1,000
capillaries (A) or myofiber (B), respectively. Values are means ± SE (n = 4 mice per group).
§P < 0.05 vs. V. G: supplementation of NGF to ischemic limb muscles improves
postischemic blood flow recovery. Line graph shows the effect of NGF supplementation for
14 days on foot postischemic BF recovery, expressed as ischemic to contralateral BF ratio.
NGF (full symbols, n = 8) improved perfusion recovery compared with vehicle (open
symbols, n = 10). Values are means ± SE. *P < 0.05 vs. time 0. §P < 0.05 vs. vehicle. H:
NGF induces angiogenesis via VEGF-A, Akt, and nitric oxide (NO). Daily injection of 20
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μg NGF for 7 days stimulates capillary growth in normoperfused muscles (closed column)
compared with vehicle-treated muscles (V, open column). The angiogenic effect of NGF
was blocked by a VEGF-neutralizing antibody (Ab-VEGF), the NO synthase inhibitor L-
nitroarginine methyl ester (L-NAME), or an adenovirus carrying dominant-negative Akt
(DNAkt). Values are means ± SE (at least n = 6 per group). §P < 0.05 vs. vehicle; +P < 0.05
vs NGF alone. [From Emanueli et al. (78).]
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FIG. 5.
Schematic representation of mechanisms by which NTs stimulate blood vessel growth. NGF
promotes angiogenesis through trkA by increasing the expression level of VEGF-A, and
through activation of the Akt intracellular pathways leading to NO production and
upregulation of matrix metalloproteinase (MMP)-2 expression. Some of the angiogenesis-
related actions of NGF have been later proven to be shared by BDNF. Moreover, BDNF
induces the mobilization of trkB+Sca1+MOMA-2+ bone marrow progenitor cells, suggesting
a promotional role of BDNF on postnatal vasculogenesis, although this hypothesis needs to
be validated.
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FIG. 6.
Neurotrophin actions on vascular smooth muscle cells. Human and rodent VSMC express
NTs, p75NTR, and trk receptors in vivo and in culture. Activaction of trkA by NGF, via
PI3K and Akt, promotes chemotaxis of human aortic VSMC, without influencing VSMC
proliferation. Moreover, the NGF/trkA receptor signal, via Shc/MAPK pathway, induces
MMP-9 expression in primary rat aortic VSMC, which, in vivo, may favor the invasion of
VSMC through the extracellular matrix and endothelial basal membrane. Stimulation with
NGF of p75NTR-expressing VSMC promotes apoptotic death.
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FIG. 7.
Prosurvival activity of NGF on cardiac myocytes. A: rat neonatal cardiomyocytes (RNMCs)
express NGF and trkA. Immunofluorescence analysis is shown of the cardiac marker α-
sarcomeric actin (green fluorescence) and NGF (red fluorescence) and merged images
(costaining results in yellow fluorescence). B: NGF is an endogenous prosurvival factor for
RNCMs. RNCMs were incubated for 48 h in serum-free medium with a goat-raised anti-
NGF neutralizing antibody (Ab-NGF) or the trkA inhibitor K252a. Controls consisted of
nonimmune goat serum (0.1% in PBS) or 0.1% DMSO, respectively. Apoptosis was
detected by cleaved caspase-3 immunostaining (green fluorescence). Nuclei were
counterstained by DAPI (blue fluorescence). The fluorescent images (×400) are
representative of the experiment. Bar graph shows the percentage of cleaved caspase 3-
positive RNCMs. Data are presented as means ± SE (n = 3). §P < 0.05 vs. 0.1% goat IgG;
**P < 0.01 vs. 0.1% DMSO. C: NGF inhibits apoptosis in rat adult cardiomyocytes. A,
isolated rat adult cardiomyocytes were maintained under normoxia or submitted to 6 h of
hypoxia followed by 18 h reoxygenation and cotreated with NGF (50 ng/ml) or its vehicle
PBS. Apoptotic nuclei were identified by TUNEL staining (green fluorescence). α-
Sarcomeric actin stains cardiomyocytes (red fluorescence). The pictures were captured at
×400 magnification. Arrows point to TUNEL-positive cardiomyocytes. Bar graphs quantify
apoptosis, which is expressed as percentage of TUNEL-positive cardiomyocyte. Data are
presented as means ± SE (n = 3). *P < 0.05 vs. PBS plus H/R (B) D: local NGF gene
transfer prevents apoptosis of cardiomyocytes in the rat infarcted heart. Myocardial
infarction was induced in adult Wistar rat. Ad.NGF or Ad.βGal (each at 108 p.f.u.) was
injected in the peri-infarct myocardium. After 7 days, the heart was arrested in diastole and
perfusion/fixed. Apoptosis of cardiomyocytes (CMs) was revealed by double staining for
TUNEL (TUNEL-positive nuclei are stained in dark brown) and the cardiac marker α-
sarcomeric actin (in purple). Nuclei were counterstained with hematoxylin. In the pictures
captured (optical microscopy, ×1,000) from Ad.NGF and Ad.βGal specimens, TUNEL-
positive apoptotic cardiomyocytes are pointed by arrows. Graph quantifies apoptosis of
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cardiomyocytes per mm2 of peri-infarct myocardium section. Values are means ± SE (n = 7)
*P < 0.05 vs. Ad.βGal. [From Caporali et al. (36).]
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FIG. 8.
Neurotrophin actions and signalling in cardiomyocytes. NGF is an autocrine prosurvival
factor for cardiomyocytes, and an increased level of this neurotrophin protects
cardiomyocytes from apoptosis. The prosurvival signal of NGF in cardiac myocytes is
mediated by trkA and downsream Akt phosphorylation. In response to Akt activation by
NGF, Forkhead transcription factors Foxo are phosphorylated and excluded from the
nucleus, thus resulting in increased cardiomyocyte survival. In primary-cultured rat neonatal
cardiomyocytes, NT-3, via trkC, activates p38 MAPK and Erk1/2, thus resulting in
increased cell size. Interestingly, in neural cells, the possibility that trk receptors can be
transactivated in response to G protein-coupled receptor (GPCR) signaling has been proven.
The GPCR adenosine receptors are expressed by cardiomyocytes, where they trigger a range
of responses, including activation PI3K. We speculate that transactivation of trk receptors by
adenosine receptors may happen in cardiomyocytes.
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FIG. 9.
Neurotrophin actions could be involved in neointima formation. Neurotrophins, which, via
trk receptors and p75NTR, regulate survival of both EC and VSMC may have a dual role in
neointima formation. In fact, the trk-mediated survival of EC may contribute to avoid
intravascular adhesion of monocytes and to maintain VSMC in a contractile rather than
proliferative status. In contrast, p75NTR triggers apoptosis of both EC (negative event) and
VSMC (possibily a positive event, as it may inhibit VSMC growth). Moreover, NGF is a
potent chemotactic agent for human aortic VSMC and, by inducing MMP-9 expression, it
may also favor VSMC invasion through the basal membrane and internal elastic lamina.
Arterial balloon injury upregulates the expression levels of NGF, BDNF, trkA, and trkB.
Increased expression levels of NTs and trk receptors persist during neointima formation.
CAPORALI and EMANUELI Page 47
Physiol Rev. Author manuscript; available in PMC 2010 March 11.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
FIG. 10.
p75NTR is implicated in diabetes-induced impairment in reparative neovascularization of
ischemic limb muscles. A: diabetes upregulates the content of endogenous p75NTR protein
in capillary EC of ischemic limb muscles. Staining of ischemic muscular sections is shown
from diabetic and normoglycemic mice with an antibody for mouse p75NTR (green
fluorescence) and with the endothelial marker isolectin-B4 (red fluorescence). Capillary EC
which are positive for p75NTR express yellow fluorescence (from merging of the red and
green fluorescence) and are pointed by arrows. Representative sections show higher density
of p75NTR-expressing capillary EC in the ischemic muscles of diabetics in comparison with
normoglycemic mice. (Original magnification: ×400; scale bar: 500 μm.). B–F: inhibition of
p75NTR signaling in diabetic limb muscles restores proper neovascularization and BF
recovery following limb ischemia. Unilateral limb ischemia was induced in diabetic and
normoglycemic mice before an adenovirus carrying a dominant negative mutant of p75NTR
(Ad.DN-p75NTR) or Ad.GFP (control) was delivered to the ischemic adductor. B, left: time
course of postischemic BF recovery (calculated by laser color Doppler flowmetry) in
diabetic and normoglycemic mice treated with Ad.DN-p75NTR (◆, diabetic; ◇,
normoglycemic) or Ad.GFP (●, diabetic; ○, normoglycemic). Right: representative laser
Doppler images taken at 14 days after induction of ischemia are shown. Squares include the
ischemic feet. C: recovery of BF (measured by Oxford Optronic) is expressed as the ratio
between the BF to ischemic muscle and the BF to the contralateral muscle at 14 days after
ischemia induction. Values are means ± SE. *P < 0.05 vs. normoglycemic mice with
Ad.GFP. §P < 0.05 vs. diabetic with Ad.GFP. D: capillary density in the ischemic adductor
at 14 days postischemia. Values are means ± SE. **P < 0.01 vs. normoglycemic mice with
Ad.GFP. §§P < 0.05 vs. diabetic with Ad.GFP. Apoptosis (revealed by TUNEL assay) (E)
and proliferation (revealed by immunhistochemistry for the proliferation antigen MCM-2)
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(F) of capillary EC in diabetic limb muscles at 14 days postischemia. Values are means ±
SE. *P < 0.05 vs. Ad.GFP. [From Caporali et al. (35).]
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